AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Data from a completed Phase I/II study of ImmunoGen Inc.'s, Cambridge, Massachusetts, Oncolysin B, show that it is well tolerated when given in combination with conventional chemotherapy to patients newly diagnosed with AIDS-related lymphoma.
These results were reported at the American Society of Hematology (ASH) Thirty-Sixth Annual Meeting in Nashville, Tennessee.
Encouraged by the Phase I/II data, and in anticipation of a pivotal study using Oncolysin B in AIDS-related lymphoma, ImmunoGen has now started a pilot study to further examine the role of the drug in this setting. These studies in AIDS-lymphoma patients are in addition to other open and completed …